Cited by 710Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Open access

Tejpar, Sabine, Stintzing, Sebastian, Ciardiello, Fortunato, Tabernero, Josep, Van Cutsem, Eric, Beier, Frank, Esser, Regina, Lenz, Heinz-Josef, Heinemann, Volker·2017·JAMA Oncology

DOI 10.1001/jamaoncol.2016.3797PMC PMC7505121

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. OBJECTIVE: To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer (FIRE-3) trial. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3 trials were classified as having left-sided or right-sided mCRC, defined, respectively, as patients whose tumors originated in the splenic flexure, descending colon, sigmoid colon, or rectum vs appendix, cecum, ascending colon, hepatic flexure, or transverse colon. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were assessed according to tumor location and treatment arm. RESULTS: In the RAS wt populations of the CRYSTAL and FIRE-3 trials, patients with left-sided tumors (n = 142 and n = 157, respectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n = 33 and n = 38, respectively). Among CRYSTAL and FIRE-3 study patients with RAS wt left-sided tumors, FOLFIRI plus cetuximab significantly improved OS relative to the respective comparators (FOLFIRI and FOLFIRI plus bevacizumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits were observed upon the addition of cetuximab to FOLFIRI in CRYSTAL, and comparable outcomes were observed between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3. A significant interaction was observed between primary tumor location and treatment for OS (CRYSTAL: hazard ratio [HR], 1.95; 95% CI, 1.09-3.48 and FIRE-3: HR, 0.40; 95% CI, 0.23-0.70) within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. CONCLUSIONS AND RELEVANCE: In the RAS wt populations of CRYSTAL and FIRE-3, patients with left-sided tumors had a markedly better prognosis than those with right-sided tumors. First-line FOLFIRI plus cetuximab clearly benefitted patients with left-sided tumors (vs FOLFIRI or FOLFIRI plus bevacizumab, respectively), whereas patients with right-sided tumors derived limited benefit from standard treatments. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.3797

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citation
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citation
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citation
The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor
Powell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.042 · Cited by 694
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citation
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citation
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Brule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335

Show all 24 references

Sorted by citations

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H., Venook, A. P., Heinemann, V., Cutsem, E. V., Pignon, J., Tabernero, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 853
Self-citation
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y. (2018) · Gastroenterology Research · doi:10.14740/gr1062w · Cited by 553
The Relevance of Primary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Self-citation
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Wasan, H. S., Gibbs, P., Sharma, N. K., Taı̈eb, J., Heinemann, V., Ricke, J., Peeters, M., Findlay, M. P. N., Weaver, A., Mills, J. N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30457-6 · Cited by 403
Self-citation
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
Lee, M. S., Menter, D. G., & Kopetz, S. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0038 · Cited by 398
Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317
Self-citation
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Loree, J. M., Pereira, A. A. L., Lam, M. S., Willauer, A. N., Raghav, K. P. S., Dasari, A. N., Morris, V. K., Advani, S., Menter, D. G., Eng, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2484 · Cited by 316
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial
Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 278
Self-citation
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour, L. R., Anand, S., Billingsley, K. G., Bisson, W. H., Cercek, A., Clarke, M. F., Coussens, L. M., Gast, C. E., Geltzeiler, C. B., Hansen, L., et al. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.006 · Cited by 281
Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3183 · Cited by 237
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 272
S3-Leitlinie – Kolorektales Karzinom
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 247
Self-citation
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy
Bhat, A. A., Nisar, S., Singh, M. K., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12295 · Cited by 251
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
Boeckx, N., Koukakis, R., de Beeck, K. O., Rolfo, C. D., Camp, G. V., Siena, S., Tabernero, J. M., Douillard, J., André, T., & Peeters, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx119 · Cited by 219
Self-citation
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Salem, M. E., Weinberg, B. A., Xiu, J., El‐Deiry, W. S., Hwang, J. J., Gatalica, Z., Philip, P. A., Shields, A. F., Lenz, H., & Marshall, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21169 · Cited by 223
Self-citation
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García‐Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z. A., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 207
Self-citation
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173
Self-citation
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Öztürk, M. A., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K. H., Christodoulou, D. K., & Pavlidis, N. A. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 172
Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location
Zhang, L., Zhao, Y., Dai, Y., Cheng, J., Gong, Z., Feng, Y., Sun, C., Jia, Q., & Zhu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01578 · Cited by 172
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Venizelos, A., Elvebakken, H., Perren, A., Nikolaienko, O., Deng, W., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlöv, A., Svensson, J., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0152 · Cited by 169
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
Mulcahy, M. F., Mahvash, A., Pracht, M., Montazeri, A. H., Bandula, S., Martin, R. C. G., Herrmann, K., Brown, E., Zuckerman, D., Wilson, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01839 · Cited by 156
Linking Gut Microbiota to Colorectal Cancer
Raskov, H., Burcharth, J., & Pommergaard, H. (2017) · Journal of Cancer · doi:10.7150/jca.20497 · Cited by 158
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Fornasier, G., Francescon, S., & Baldo, P. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0791-0 · Cited by 134
The current status of treatment for colorectal cancer in China
Zhang, Y., Chen, Z., & Li, J. (2017) · Medicine · doi:10.1097/md.0000000000008242 · Cited by 135
The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer
Sun, J., Fei, F., Zhang, M., Li, Y., Zhang, X., Zhu, S., & Zhang, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5663-8 · Cited by 133
Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer
Narayanan, S., Kawaguchi, T., Peng, X., Qi, Q., Liu, S., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-49878-4 · Cited by 138
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Sjoquist, K. M., Renfro, L. A., Simes, R. J., Tebbutt, N. C., Clarke, S. J., Seymour, M., Adams, R., Maughan, T., Saltz, L. B., Goldberg, R. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx253 · Cited by 129
Self-citation
CD44v6 engages in colorectal cancer progression
Ma, L., Dong, L., & Chang, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1265-7 · Cited by 128
Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R. D., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Seventer, E. E. V., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 130
Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis
Meijer, L. L., Alberga, A. J., de Bakker, J. K., van der Vliet, H. J., Large, T. Y. S. L., van Grieken, N. C. T., de Vries, R., Daams, F. D., Zonderhuis, B. M., & Geert Kazemier, M. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6567-6 · Cited by 123
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
Colon Cancer in Young Adults: Trends and Their Implications
Weinberg, B. A., & Marshall, J. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0756-8 · Cited by 123
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis
Rumpold, H. F., Niedersüß‐Beke, D., Heiler, C., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07656-w · Cited by 122
The Role of Maintenance Strategies in Metastatic Colorectal Cancer
Sonbol, M. B., Mountjoy, L. J., Firwana, B., Liu, A. J., Almader‐Douglas, D., Mody, K., Hubbard, J. M., Borad, M. J., Ahn, D. H., Murad, M. H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4489 · Cited by 113
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
Cremolini, C., Antoniotti, C., Lonardi, S., Bergamo, F., Cortesi, E., Tomasello, G., Moretto, R., Ronzoni, M., Racca, P., Loupakis, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy140 · Cited by 112
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Bianchi, A. S., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 116
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 110
Recent developments in the treatment of metastatic colorectal cancer
Loree, J. M., & Kopetz, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714997 · Cited by 108
The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future
Foster, J. M., Zhang, C., Rehman, S. U., Sharma, P., & Alexander, H. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21749 · Cited by 105
Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence?
Deng, Y. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0500-2 · Cited by 101
Serum extracellular vesicles contain SPARC and LRG1 as biomarkers of colon cancer and differ by tumour primary location
Zhong, M., Chen, Y., Xiao, Y., Xu, L., Zhang, G., Lu, J., Qiu, H., Ge, W., & Wu, B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.003 · Cited by 97
DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies
Weisenberger, D. J., Liang, G., & Lenz, H. J. (2017) · Oncogene · doi:10.1038/onc.2017.374 · Cited by 96
Self-citation
The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer
Creasy, J. M., Sadot, E., Koerkamp, B. G., Chou, J. F., Gönen, M., Kemeny, N. E., Saltz, L. B., Balachandran, V. P., Kingham, T. P., DeMatteo, R. P., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6264-x · Cited by 93
Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
Ulivi, P., Canale, M., Passardi, A., Marisi, G., Valgiusti, M., Frassineti, G. L., Calistri, D., Amadori, D., & Scarpi, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010307 · Cited by 91
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
Cercek, A., Braghiroli, M. I., Chou, J. F., Hechtman, J. F., Kemeny, N. E., Saltz, L. B., Capanu, M., & Yaeger, R. D. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0400 · Cited by 88
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., von Weikersthal, L. F., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 89
Self-citation
Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype
Yang, S. Y., Cho, M. S., & Kim, N. K. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1442217 · Cited by 89
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update
Wang, F., Chen, G., Zhang, Z., Yuan, Y., Wang, Y., Gao, Y., Sheng, W., Wang, Z., Li, X., Yuan, X., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12639 · Cited by 91
The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82
“Moreover, the addition of molecular-targeted agents, such as bevacizumab, cetuximab, or pan-itumumab, has extended survival beyond 30 months [37–39].”
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 80
Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Venizelos, A., Elvebakken, H., Perren, A. A., Nikolaienko, O., Deng, W., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., Sundlöv, A., Svensson, J. B., et al. (2021) · doi:10.48350/160936 · Cited by 77
PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Xu, J.-M., Wang, Y., Wang, Y., Wang, Y., Liu, T., Ni, M., Li, M., Li, L., Ge, F.-J., Gong, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2738 · Cited by 78
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Guren, T. K., Thomsen, M., Kure, E. H., Sørbye, H., Glimelius, B. L. G., Pfeiffer, P., Osterlund, P. J., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 75
A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
Ciombor, K. K., & Bekaii‐Saab, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0203 · Cited by 74
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma
Shamir, E. R., Devine, W. P., Pekmezci, M., Umetsu, S. E., Krings, G., Federman, S., Cho, S., Saunders, T. A., Jen, K., Bergsland, E. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0131-6 · Cited by 71
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
Smabers, L. P., Wensink, G. E., Veríssimo, C. S., Koedoot, E., Pitsa, K.-C., Huismans, M. A., Barón, C. H., Doorn, M., Iersel, L. V., Cirkel, G. A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02980-6 · Cited by 84
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
Wang, C., Shahjehan, F., Merchea, A., Li, Z., Bekaii‐Saab, T., Grothey, A. F., Colibaseanu, D., & Kasi, P. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00076 · Cited by 70
DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients
Liu, X., Fu, J., Bi, H., Ge, A., Xia, T., Liu, Y., Sun, H., Li, D., & Zhao, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-6436-0 · Cited by 68
Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 70
Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer
Kim, K., Castro, E. J., Shim, H., Advincula, J. V. G., & Kim, Y. W. (2018) · Annals of Coloproctology · doi:10.3393/ac.2018.12.17 · Cited by 68
Colorectal Cancer: Why Does Side Matter?
Gallois, C., Pernot, S., Zaanan, A., & Taı̈eb, J. (2018) · Drugs · doi:10.1007/s40265-018-0921-7 · Cited by 68
Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 63
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 64
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection
Duwe, G., Knitter, S., Pesthy, S., Beierle, A. S., Bahra, M., Schmelzle, M., Schmuck, R. B., Lohneis, P., Raschzok, N., Öllinger, R., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.05.008 · Cited by 65
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
Yoshino, T., Portnoy, D. C., Obermannova, R. L., Bodoky, G., Prausová, J., García‐Carbonero, R., Ciuleanu, T., Alfonso, P. G., Cohn, A. L., Cutsem, E. V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy461 · Cited by 64
Self-citation
Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study
Shida, D., Inoue, M., Tanabe, T., Moritani, K., Tsukamoto, S., Yamauchi, S., Sugihara, K., & Kanemitsu, Y. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01706-7 · Cited by 63
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
Aasebø, K., Dragomir, A., Sundström, M., Mezheyeuski, A., Edqvist, P.-H. D., Eide, G. E., Pontén, F., Pfeiffer, P., Glimelius, B. L. G., & Sørbye, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00008 · Cited by 62
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020
Dong, C., Ding, Y., Weng, S., Li, G., Huang, Y., Hu, H., Zhang, Z., Zhang, S., & Yuan, Y. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.02 · Cited by 60
TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer
Pan, M., Jiang, C., Tse, P., Achacoso, N., Alexeeff, S., Solorzano, A. V., Chung, E., Hu, W., Truong, T.-G., Arora, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02014 · Cited by 59
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Cabibbo, G., Celsa, C., Rimassa, L., Torres, F., Rimola, J., Kloeckner, R., Bruix, J., Cammà, C., & Reig, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.018 · Cited by 62
KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010–2013
Charlton, M. E., Kahl, A. R., Greenbaum, A. A., Karlitz, J. J., Lin, C. H., Lynch, C. F., & Chen, V. W. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7011 · Cited by 58
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors
Puccini, A., Lenz, H., Marshall, J. L., Arguello, D., Raghavan, D., Korn, W. M., Weinberg, B. A., Poorman, K. A., Heeke, A. L., Philip, P. A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0117 · Cited by 60
Self-citation
Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
Salvatore, L., Aprile, G., Arnoldi, E., Aschele, C., Carnaghi, C., Cosimelli, M., Maiello, E., Normanno, N., Sciallero, S., Valvo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000147 · Cited by 52
Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer
Aljehani, M. A., Morgan, J. W., Guthrie, L., Jabo, B., Ramadan, M. M., Bahjri, K. A., Lum, S. S., Selleck, M. J., Reeves, M. E., Garberoglio, C. A., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.3466 · Cited by 53
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 52
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer
Lee, D., Han, S., Cha, Y., Bae, J. M., Kim, H., Lyu, J., Han, H., Kim, H., Jang, H. S., Bang, D., et al. (2017) · Cancer · doi:10.1002/cncr.30760 · Cited by 52
Colorectal Cancer Biomarkers in the Era of Personalized Medicine
Patel, J. N., Fong, M. K., & Jagosky, M. H. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010003 · Cited by 55
TIMP1 promotes cell proliferation and invasion capability of right‐sided colon cancers via the FAK /Akt signaling pathway
Ma, B., Ueda, H., Okamoto, K., Bando, M., Fujimoto, S., Okada, Y., Kawaguchi, T., Wada, H., Miyamoto, H., Shimada, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15567 · Cited by 51
Heterogeneity of colon cancer: from bench to bedside
Merlano, M. C., Granetto, C., Fea, E., Ricci, V., & Garrone, O. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000218 · Cited by 52
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Goldberg, R. M., Montagut, C. O., Wainberg, Z. A., Ronga, P., Audhuy, F., Taı̈eb, J., Stintzing, S., Siena, S., & Santini, D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000353 · Cited by 51
Self-citation
Simultaneous versus staged resection for synchronous colorectal liver metastases: A population-based cohort study
Bogach, J., Wang, J., Griffiths, C. D., Parpia, S., Saskin, R., Hallet, J. I., Ruo, L., Simunovic, M. R. I., & Serrano, P. E. (2019) · International Journal of Surgery · doi:10.1016/j.ijsu.2019.12.009 · Cited by 50
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 50
Self-citation
Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes
Jin, M., Shang, F., Wu, J., Fan, Q., Chen, C., Fan, J., Liu, L., Nie, X., Zhang, T., Cai, K., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.727937 · Cited by 50
Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis
Li, Y., Feng, Y., Dai, W., Li, Q., Cai, S., & Peng, J. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.10.005 · Cited by 49
The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review
Boeckx, N., Janssens, K., Camp, G. V., Rasschaert, M. A., Papadimitriou, K., Peeters, M., & de Beeck, K. O. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.003 · Cited by 48
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
Laurent‐Puig, P., Grisoni, M.-L., Heinemann, V., Liebaert, F., Neureiter, D., Jung, A., Montestruc, F., Gaston‐Mathé, Y., Thiébaut, R., & Stintzing, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1324 · Cited by 48
Self-citation
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 49
Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies
Boeckx, N., Koukakis, R., de Beeck, K. O., Rolfo, C. D., Camp, G. V., Siena, S., Tabernero, J. M., Douillard, J., André, T., & Peeters, M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.03.005 · Cited by 48
Self-citation

Authors: Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V.
Affiliations: Universitair Ziekenhuis Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
University of Campania "Luigi Vanvitelli" (IT)
Universitat Autònoma de Barcelona (ES)
Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium
Merck KGaA, Darmstadt (Germany) (DE)
University of Southern California (US)
Corresponding author: Tejpar, Sabine
ORCID: Tejpar, Sabine
Stintzing, Sebastian
Ciardiello, Fortunato
Tabernero, Josep
Beier, Frank
Esser, Regina
Lenz, Heinz-Josef
Heinemann, Volker
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2017-02-01
Volume: 3
Issue: 2
Pages: 194
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.3797
PMC: PMC7505121
OpenAlex: W2531319683
Cited by: 709
References: 24
Citations by year: 2026: 19 · 2025: 35 · 2024: 64 · 2023: 48 · 2022: 70 · 2021: 89 · 2020: 85 · 2019: 97 · 2018: 102 · 2017: 96
FWCI: 53.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders: National Cancer Institute (P30CA014089)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: metastatic colorectal cancer, RAS wild-type, primary tumor site, cetuximab, FOLFIRI, bevacizumab, first-line therapy, progression-free survival, overall survival, objective response rate, predictive biomarkers, CRYSTAL trial, FIRE-3 trial, EGFR inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks